PharmAla Biotech drives clinical MDMA development, targets neuropathic pain and brain trauma

PharmAla Biotech Holdings CEO Nicholas Kadysh joined Steve Darling from Proactive’s OTC studio in New York City to discuss the company’s ongoing progress in clinical MDMA supply and development. Kadysh highlighted that PharmAla was founded as a dedicated MDMA company, and today operates as one of the world’s leading producers and suppliers of MDMA for clinical use, particularly in Canada and Australia. In addition to supplying MDMA for patient treatments and clinical trials, the company is developing novel analogs for a range of medical conditions. The company holds a controlled substances license from Health Canada, enabling legal manufacture and supply of MDMA. PharmAla collaborates with leading academic and government institutions, including Harvard, Yale, Johns Hopkins, and the University of Arkansas. Kadysh noted the company’s involvement in a new Canadian study funded by the Canadian Institutes for Health Research, which explores MDMA for neuropathic pain, with PharmAla supplying the compound. The company is also advancing MDMA analogs targeting social anxiety and brain trauma, including post-stroke recovery and traumatic brain injury. “We view part of our mission as making sure actual patients get the medication, not just clinical researchers,” Kadysh emphasized, underscoring the company’s commitment to real-world patient access. The interview also highlighted PharmAla’s collaboration with U.S. government agencies, including the Veterans Affairs Administration and Defense Health Agency, for military-related clinical trials. #proactiveinvestors #pharmalabiotechholdings #cse #mdma #otc #mdxxf #PharmAlaBiotech #MDMAResearch #BiotechNews #ClinicalTrials #MentalHealthInnovation #NeuropathicPain #DrugDevelopment #ControlledSubstances #HealthCanada #VeteransHealth #BrainTraumaTreatment #SocialAnxietyRelief